- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
ROSEN Encourages Aquestive Therapeutics Investors to Secure
Law firm urges investors to take action following company developments.
Apr. 1, 2026 at 6:00pm
Got story updates? Submit your updates here. ›
The law firm ROSEN is encouraging investors in Aquestive Therapeutics, Inc. to take action and secure their interests following recent developments at the pharmaceutical company. The announcement comes as Aquestive faces an uncertain future amid regulatory and financial challenges.
Why it matters
Aquestive Therapeutics is a small but promising pharmaceutical firm that has faced setbacks in bringing new products to market. The ROSEN law firm's call for investors to take action suggests there may be concerns about the company's long-term viability, which could impact shareholders.
The details
ROSEN, a global investor rights law firm, announced that it is investigating potential securities claims on behalf of shareholders of Aquestive Therapeutics, Inc. The investigation follows recent developments at the company, including regulatory and financial challenges that have raised concerns about Aquestive's future prospects.
- The announcement from ROSEN was made on April 1, 2026.
The players
ROSEN
A global investor rights law firm that is investigating potential securities claims on behalf of Aquestive Therapeutics shareholders.
Aquestive Therapeutics, Inc.
A pharmaceutical company that has faced regulatory and financial challenges in bringing new products to market.
The takeaway
The ROSEN law firm's call for Aquestive Therapeutics investors to take action suggests the company may be facing an uncertain future, which could have significant implications for shareholders. This development highlights the risks and challenges that can arise for investors in small, innovative pharmaceutical firms.
